Last reviewed · How we verify
E-602
At a glance
| Generic name | E-602 |
|---|---|
| Sponsor | Palleon Pharmaceuticals, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (PHASE1, PHASE2)
- HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |